The Food & Drug Administration on Wednesday approved U.S. marketing of the first in a new class of sleep drugs that targets the brain's wakefulness centers to speed the onset of sleep and reduce nighttime awakening. The new medication, which goes by the generic name suvorexant, is to be...
via L.A. Times - Science http://ift.tt/1t0FsoP
via L.A. Times - Science http://ift.tt/1t0FsoP
No comments:
Post a Comment